2014 Review: The New York False Claims Act

by Akin Gump Strauss Hauer & Feld LLP

There was significant activity in 2014 in matters involving the New York False Claims Act (NY FCA). This review summarizes the legislative activity, case law developments and noteworthy settlements in 2014.

I. Legislative Activity

In 2011, the Inspector General of the U.S. Department of Health and Human Services (HHS OIG) determined that that the NY FCA (among other state FCAs) was not as robust as the federal False Claims Act (FCA), and that New York would not qualify for an increased allocation of recoveries in cases involving the submission of false claims to Medicaid if it did not amend its FCA to bring it in line with the federal FCA. Section 1909 of the federal Social Security Act provides for an added ten percent allocation to states from any FCA recovery shared by the federal and state government in FCA cases involving Medicaid claims. Only states whose FCAs “are at least as effective in rewarding and facilitating qui tam actions for false and fraudulent claims” qualify for this additional ten percent recovery. In response to the HHS OIG’s findings, NY amended its FCA in 2013 and also proposed changes to procedural regulations implementing the NY FCA that have since been adopted. In February 2014, HHS OIG determined that both the New York FCA and the accompanying procedural regulations comply with Section 1909’s requirements.1

II. Case Law Developments

A. Tax Fraud

New York amended its False Claims Act in 2010 to, among other things, reach tax fraud. N.Y. State Fin. Law § 189(4)(a). The biggest news of 2014 involved the New York Attorney General’s (AG) first lawsuit alleging tax fraud, People v. Sprint Nextel Corp., which has now survived a motion to dismiss and an appeal. In April 2012, the AG filed a complaint against Sprint, alleging that Sprint deliberately “under-collect[ed] and underpay[ed] millions of dollars in … taxes on flat-rate access charges for wireless calling plans.” Sprint moved to dismiss the complaint a few months later, arguing that it was not liable for violating the FCA and that, even if it were liable, an award of damages for conduct pre-dating the 2010 Amendments would violate the relevant Ex Post Facto clause of the federal constitution. Sprint appealed after a trial court denied its motion in June 2013.

In February 2014, the Appellate Division unanimously affirmed. It held that the complaint adequately alleged that Sprint violated the NY FCA, Executive Law Sec. 63 (12) and Article 28 of the Tax Law by knowingly making false statements material to an obligation to pay sales tax. The court further found that the applicable Tax Law provision is not preempted by the Federal Mobile Telecommunications Sourcing Act (4 USC 116 et seq.).

Finally, the court held that Sprint failed “to show that the Act’s sanction of civil penalties, including treble damages, is so punitive in nature and effect as to have its retroactive effect barred” by the constitution. 114 A.D.3d. at 623. A federal district court has since echoed that conclusion outside the tax-fraud context, permitting claims based on conduct that occurred before New York enacted its FCA.”2 This issue will eventually lose significance because the NY FCA has a ten-year statute of limitations. See N.Y. State Fin. Law § 192(1). But NY taxpayers should be aware that they may be sued for conduct that pre-dates the 2010 amendments.

B. The Pleading Standard

Two decisions involving Novartis Pharmaceuticals Corp. underscored that FCA plaintiffs must allege fraud with the requisite particularity to survive a motion to dismiss.

In United States ex rel. Kester v. Novartis Pharm. Corp., No. 11 Civ. 8196 (S.D.N.Y.), the court considered allegations that Novartis paid kickbacks in exchange for the promotion of some of its drugs. In June 2014, the court denied part of a motion to dismiss state and federal FCA claims involving some—but not all—of those medications. The court acknowledged the sufficiency of drug-specific allegations “based on actual Medicare and Medicaid claims data and broken down by pharmacy.” But it dismissed claims involving other drugs because the allegations lacked “specifics (such as dollar amounts or the number of claims)” involved. (For more on the case, see our earlier post.)

Several months later, in United States ex rel. Bilotta v. Novartis Pharm. Corp., No. 11 Civ. 0071 (S.D.N.Y.), a different judge on the same court considered additional kickback allegations against Novartis. Although the court held that the government adequately detailed the alleged fraud, it applied a stricter pleading standard than the one urged by the government. The court rejected the approach set out by the 5th Circuit in Grubbs v. Kanneganti, 565 F.3d 180 (5th Cir. 2009), which requires only the “particular details of a scheme paired with reliable indicia that lead to a strong inference that claims were actually submitted.” Instead, the district court concluded that an FCA plaintiff must plead “the particulars of the false claims themselves.” The Bilotta court found that the complaint satisfied that standard because it included “hundreds of pages of spreadsheets listing particular false claims.”

III. Noteworthy Settlements

A. Tax Fraud

The Sprint decision likely induced two settlements involving tax fraud allegations. In May 2014, the AG announced a $6.2 million settlement with Lantheus Medical Imaging Inc. to resolve tax fraud allegations. Three months later, the AG announced a $1.56 million settlement with appliance retailer Topline Appliance Center to resolve allegations that it did not “collect and pay sales taxes and corporate franchise taxes to New York over an almost 10-year period.”

B. Health Care Fraud

Some of the year’s largest settlements concerned kickbacks and off-label marketing.

  • Endo Pharmaceuticals agreed to pay $173 million—in addition to nearly $21 million in criminal penalties and forfeitures—to settle claims that it promoted the drug Lidoderm for off-label uses. (AG Press Release.) Although several states and the federal government participated in the settlement, more than $25 million was earmarked for the New York Medicaid program.
  • CareFusion agreed to pay $40 million to settle claims with all fifty states, the federal government, and the District of Columbia, “resolving civil allegations of unlawful marketing practices and the payment of kickbacks aimed at promoting sales of CareFusion’s surgical preparation solution, Chloraprep.” (AG Press Release.) New York’s share totaled over $2 million. (Settlement at 5.)
  • BioScrip, Inc. agreed to pay more than $15 million to resolve allegations that it participated in an alleged kickback scheme involving the drug Exjade.3 Of that $15 million, $895,000 will be paid to New York to resolve kickback claims relating to New York Medicaid recipients. (AG Press Release.)
  • Sorkin’s Ltd. Rx. agreed to pay $846,244 to resolve allegations that it “had made false statements to obtain prior authorizations for certain prescription drugs, restocked and resold unused dosages of drugs for which it had already submitted claims and received payment, and submitted false claims to Medicaid and Medicare Part D.” (Akin Gump Coverage.) New York State will receive $465,423 of the settlement.
  • Brooklyn Plaza Medical Center agreed to pay $600,000 “to resolve allegations that the diagnostic and treatment center ran a satellite facility … without an operating certificate” and “disguised the satellite facility’s Medicaid billings to make them appear as if the services were rendered at the Brooklyn Plaza Medical Center, not the satellite center.” (AG Press Release.)
  • Two defendants entered into a $15.5 million settlement “to resolve allegations that [a] radiology practice … submitted [more than 40,000] false claims to the Medicaid and Medicare programs for diagnostic outpatient imaging services that were not specifically ordered by a treating physician[,] not medically necessary,” and in some cases, “not even performed.” (AG Press Release.) New York will receive approximately $3 million from the settlement.
  • A foster-care services provider agreed to pay $250,000 to resolve allegations that the provider billed “Medicaid for the care of children while they were absent from [a foster care] program.” (AG Press Release.)
  • A nursing home and its owner pledged $2.2 million to resolve claims that they submitted over 62,000 false claims from 2002 to 2006. According to the AG’s press release, the defendants “routinely stated that residents were receiving treatments, including for oxygen and suctioning, when such treatments where neither required nor given.” The defendants also falsified medical records to cover up the scheme—prompting two criminal convictions.

C. Government Contractors

  • Office Depot agreed to pay $475,000 to “to resolve allegations that [it] overcharged New York state agencies for offices supplies.” (Akin Gump Coverage.)
  • We expect more overpayment news in 2015 as the United States Attorney General intervened in a suit alleging that Symantec overcharged New York and other states for computer software.

1 http://oig.hhs.gov/fraud/docs/falseclaimsact/NewYork.pdf

2 U.S. ex rel. Bilotta v. Novartis Pharm. Corp., No. 11 Civ. 0071 (PGG) (S.D.N.Y.).

3 BioScrip was a co-defendant in the Kester case described above.

Written by:

Akin Gump Strauss Hauer & Feld LLP

Akin Gump Strauss Hauer & Feld LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.